ARCHIVES

Also R01 payline likely to fall below 20th percentile in FY04.

This article is from The Cancer Letter archive.

Vol. 29 No. 35 | September 26, 2003

Download PDF Visit The Full Archive

Related Articles

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

October 17, 2014

Former NCI Lab Deputy Charged With Two Criminal Counts

January 17, 1992

In Brief: Li, Gart Retire Forom NCI; Clifford Heads Diet Branch; ASTRO Meeting Nov. 4-8 In Washington

October 18, 1991

Vaccine Increases PFS by 4 Months In Phase II Per-Protocol Analysis

June 27, 2014

High Response Rate of Hairy Cell Leukemia Patients to Immunotoxin Treatment In Phase I

April 27, 2001

DCE Board Approves Recompetition Of Two Major Contracts

October 30, 1987